Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGuIX Gadolinium-based Nanoparticles with Stereotactic Radiation for Brain Metastases
NCT04899908Phase 2Recruiting
- Sponsor
- Brigham and Women's Hospital
- Start
- Sep 2021
- Primary completion
- Apr 2028
- Modality
- Nanoparticles
- Countries
- 1
01
Overview
A Phase 2 trial of AGuIX in brain metastases, sponsored by Brigham and Women's Hospital. Started Sep 2021; status: recruiting.
02
Drugs
AGuIX
03
Conditions
brain metastases
Beyond the preview
Go deeper on NCT04899908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04899908.